<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00943059</url>
  </required_header>
  <id_info>
    <org_study_id>MEC 09-3-033</org_study_id>
    <secondary_id>CTMM2008172</secondary_id>
    <secondary_id>EFSD10122008</secondary_id>
    <secondary_id>ZonMw91896618</secondary_id>
    <nct_id>NCT00943059</nct_id>
  </id_info>
  <brief_title>Cross-over Study on Effect of Lipid Lowering by Acipimox on Cardiac and Skeletal Muscle Mitochondrial Function</brief_title>
  <acronym>ACP</acronym>
  <official_title>The Effect of Lipid Lowering by Acipimox on Cardiac and Skeletal Muscle Mitochondrial Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Translational Molecular Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Accumulation of lipid in skeletal and cardiac muscle has been associated with insulin
      resistance and diabetic cardiomyopathy. In skeletal muscle, lipotoxic damage has been
      suggested to lead to dysfunction of mitochondria. It remains unknown whether lipotoxicity
      leads to mitochondrial dysfunction in heart as well, and if so, whether this also leads to
      cardiomyopathy (failure of the heart). Although it has been shown that lipid lowering agents
      can improve insulin sensitivity, the effect of lowering free fatty acids on cardiac and
      skeletal muscle mitochondrial function remains unknown. In this study the investigators want
      to investigate whether lowering cardiac and muscular lipid content will improve mitochondrial
      and cellular function in type 2 diabetic patients.

      To this end, type 2 diabetic patients and body mass index (BMI)-matched controls will be
      included in a blinded cross-over design, in which subjects will receive a lipid lowering
      agent (Acipimox) or placebo for 2 weeks in random order. During treatment, diabetes
      medication will be stopped. Baseline measurements will be performed prior to the study and
      after each treatment to assess cardiac and muscular lipid accumulation, cardiac function,
      mitochondrial function and insulin sensitivity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in mitochondrial function</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>changes in cardiac function</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>lipid accumulation in ectopic tissue (cardiac and skeletal muscle)</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxidative stress markers</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Cardiomyopathy, Dilated</condition>
  <arm_group>
    <arm_group_label>Acipimox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Acipimox or a placebo in random order. Acipimox is a commercially available and registrated drug, that lowers free fatty acids by inhibiting hormone sensitive lipase in the peripheral adipose tissue. No serious side-effects are known other than rare anaphylactic reactions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cellulosum mycrocryst capsula</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive Acipimox or a placebo in random order. Acipimox is a commercially available and registrated drug, that lowers free fatty acids by inhibiting hormone sensitive lipase in the peripheral adipose tissue. No serious side-effects are known other than rare anaphylactic reactions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acipimox</intervention_name>
    <description>A capsula is given with 250mg Acipimox, 3dd; 1 after each meal. This will be done during 14 days.</description>
    <arm_group_label>Acipimox</arm_group_label>
    <other_name>Olbetam</other_name>
    <other_name>Nedios</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cellulosum Mycrocryst</intervention_name>
    <description>Capsule with cellulosum powder; this has to be taken 3 dd; 1 after each meal during 14 days.</description>
    <arm_group_label>Cellulosum mycrocryst capsula</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or postmenopausal females

          -  Age 40-70 years

          -  Obese (BMI &gt; 30 kg/m2), non-insulin dependent type 2 diabetic patients and BMI matched
             control subjects without diabetes.

          -  Generally healthy with specifically no known cardiovascular disease, dyslipidemia, or
             gastric ulcers (contra-ind. of Acipimox), which can affect the study parameters.

          -  Must be on sulphonylurea(SU)- derivate or metformin therapy for at least six months
             with a constant dose for at least two months, or on dietary treatment for at least six
             months

          -  Well-controlled diabetes: HbA1c&lt;8%.

          -  Control subjects must have a plasma glucose lower than 6,1 mmol/L.

          -  Stable dietary habits (no weight loss/gain &gt; 3 kg in the last 6 months)

        Exclusion Criteria:

          -  Known cardiovascular disease, dyslipidemia, hepatic or renal failure and gastric
             ulcers.

          -  Insulin dependent Diabetic patients.

          -  Use of lipid lowering agents, except from Statins, as these do not affect
             triglycerides levels (with exception to Lipitor).

          -  Use of Thiazolidines (glitazone/rosiglitazone/pioglitazone/troglitazone)

          -  Use of anti-coagulants (not thrombocyte-aggregation inhibitors)

          -  Aberrant ECG (with signs of ischemia or cardiac failure or arrythmia's)

          -  Weight gain/loss &gt; 3 kg in the last 6 months.

          -  Hb &lt; 7,3 in women, and &lt; 7,8 in men.

          -  Contraindications for MRI scans:

               -  Electronic implants such as pacemakers or neurostimulator

               -  Iron-containing corpora aliena in eyes or brain

               -  Some hearing aids and artificial (heart) valves which are contraindicated for MRS

               -  Claustrophobia

          -  Subjects, who do not want to be informed about unexpected medical findings, or do not
             wish that their physician is informed, cannot participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Schrauwen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Centre</name>
      <address>
        <city>Maastricht</city>
        <zip>6200MD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.maastrichtuniversity.nl</url>
    <description>Website of location of trail.</description>
  </link>
  <link>
    <url>http://www.hb.unimaas.nl/</url>
    <description>Website of department of Human Biology, who conduct trail.</description>
  </link>
  <reference>
    <citation>Schrauwen-Hinderling VB, Kooi ME, Hesselink MK, Jeneson JA, Backes WH, van Echteld CJ, van Engelshoven JM, Mensink M, Schrauwen P. Impaired in vivo mitochondrial function but similar intramyocellular lipid content in patients with type 2 diabetes mellitus and BMI-matched control subjects. Diabetologia. 2007 Jan;50(1):113-20. Epub 2006 Nov 9.</citation>
    <PMID>17093944</PMID>
  </reference>
  <reference>
    <citation>Phielix E, Schrauwen-Hinderling VB, Mensink M, Lenaers E, Meex R, Hoeks J, Kooi ME, Moonen-Kornips E, Sels JP, Hesselink MK, Schrauwen P. Lower intrinsic ADP-stimulated mitochondrial respiration underlies in vivo mitochondrial dysfunction in muscle of male type 2 diabetic patients. Diabetes. 2008 Nov;57(11):2943-9. doi: 10.2337/db08-0391. Epub 2008 Aug 4.</citation>
    <PMID>18678616</PMID>
  </reference>
  <reference>
    <citation>De Feyter HM, Lenaers E, Houten SM, Schrauwen P, Hesselink MK, Wanders RJ, Nicolay K, Prompers JJ. Increased intramyocellular lipid content but normal skeletal muscle mitochondrial oxidative capacity throughout the pathogenesis of type 2 diabetes. FASEB J. 2008 Nov;22(11):3947-55. doi: 10.1096/fj.08-112318. Epub 2008 Jul 24.</citation>
    <PMID>18653763</PMID>
  </reference>
  <reference>
    <citation>Schrauwen-Hinderling VB, Roden M, Kooi ME, Hesselink MK, Schrauwen P. Muscular mitochondrial dysfunction and type 2 diabetes mellitus. Curr Opin Clin Nutr Metab Care. 2007 Nov;10(6):698-703. Review.</citation>
    <PMID>18089950</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2009</study_first_submitted>
  <study_first_submitted_qc>July 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2009</study_first_posted>
  <last_update_submitted>May 13, 2013</last_update_submitted>
  <last_update_submitted_qc>May 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mitochondrial function</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Cardiomyopathy</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>lipid lowering</keyword>
  <keyword>triglycerides</keyword>
  <keyword>Acipimox</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acipimox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

